--- title: "Libidon" canonical_url: https://bestpeptidecalculator.app/library/libidon description: "Peptide preparation derived from prostate tissue and marketed as a tissue-specific bioregulator in the Khavinson tradition. Not FDA-approved for any indication. No study of Libidon itself is indexed in PubMed, controlled or otherwise; the studies cited here are class-level work on short peptide bioregulators." updated: 2026-11-07 publisher: Peptide Library notice: "Research and educational use only. Not medical advice." --- # Libidon Libidon is a khavinson peptide bioregulator. The Khavinson bioregulator hypothesis holds that short peptides extracted from a given tissue act preferentially on that same tissue, with proposed effects on gene expression and protein synthesis. Most supporting work comes from a single research group, is published largely in Russian-language journals, and has not been independently replicated in controlled human trials. Peptide preparation derived from prostate tissue and marketed as a tissue-specific bioregulator in the Khavinson tradition. Not FDA-approved for any indication. No study of Libidon itself is indexed in PubMed, controlled or otherwise; the studies cited here are class-level work on short peptide bioregulators. Categories: Experimental. ## Classification - Type: Khavinson peptide bioregulator / research - Mechanism class: Short Peptide Bioregulator - Development stage: Research only - Regulatory class: Research compound, not FDA-approved ## Mechanism The Khavinson bioregulator hypothesis holds that short peptides extracted from a given tissue act preferentially on that same tissue, with proposed effects on gene expression and protein synthesis. Most supporting work comes from a single research group, is published largely in Russian-language journals, and has not been independently replicated in controlled human trials. Claims specific to the prostate preparation should be read as marketing rather than established pharmacology. ## Evidence - Evidence level: Insufficient Evidence - Highest documented: None documented - Human trials: 0 - Controlled human trials: 0 - Preclinical sources: 0 No human dose is established for this compound. Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess. ### Studies 1. Influence of adding zinc arginyle-glycinate to improve efficacy of bioregulatory peptides of the prostate gland in treatment of patients with impaired sperm parameters. Georgian Med News. 2022. 2022. Human study (early or uncontrolled). Population: Men aged 25–45 with chronic abacterial prostatitis and reproductive problems (n=98; 49 given Prostatilen as the comparison arm). Total motile sperm rose by 4.1% with Prostatilen; the zinc-containing version (Prostatilen AC) did better on sperm measures. Research on a related compound, not this one. Limitations: Studied an analog, not Libidon itself [Source](https://pubmed.ncbi.nlm.nih.gov/36318852/) ## Safety Human safety basis: No controlled human safety data Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use.. ## Regulatory status Libidon is not an FDA-approved product. It is sold for laboratory research and has no approved medical use. - FDA status: Not Approved - Availability: Research-Only ## Frequently asked questions ### What is Libidon? Peptide preparation derived from prostate tissue and marketed as a tissue-specific bioregulator in the Khavinson tradition. Not FDA-approved for any indication. No study of Libidon itself is indexed in PubMed, controlled or otherwise; the studies cited here are class-level work on short peptide bioregulators. ### How does Libidon work? The Khavinson bioregulator hypothesis holds that short peptides extracted from a given tissue act preferentially on that same tissue, with proposed effects on gene expression and protein synthesis. Most supporting work comes from a single research group, is published largely in Russian-language journals, and has not been independently replicated in controlled human trials. ### Is Libidon FDA approved? No. Libidon is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use. ### What peptides are similar to Libidon? Compounds most often compared with Libidon include Bonomarlot, Bronchogen, Cardiogen and Cartalax. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ. ## References - [Class-level evidence — Khavinson VK. Peptides and Ageing. Neuro Endocrinol Lett, 2002](https://pubmed.ncbi.nlm.nih.gov/12374906/) - [Class-level evidence — Tissue-specific effects of peptides. Bull Exp Biol Med, 2001](https://pubmed.ncbi.nlm.nih.gov/11713572/) - [Class-level evidence — Peptide bioregulation of aging: results and prospects — Biogerontology, 2010](https://pubmed.ncbi.nlm.nih.gov/19830585/) - [Class-level evidence — Mechanisms underlying geroprotective effects of peptides — Bull Exp Biol Med, 2002](https://pubmed.ncbi.nlm.nih.gov/12170291/) - [Class-level evidence — Epigenetic mechanisms of peptide-driven regulation and neuroprotective protein FKBP1b — Mol Biol (Mosk), 2019](https://pubmed.ncbi.nlm.nih.gov/31099784/)